Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Ibrance Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Ibrance (palbociclib) Step Therapy

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and step therapy coverage for Ibrance in members, primarily those with HR-positive, HER2-negative advanced, metastatic, recurrent unresectable, or stage IV breast cancer. Members new to Ibrance must satisfy applicable coverage criteria, while members currently receiving Ibrance may continue therapy when continuation conditions are met.

    Policy Summary
    PayerUnitedHealthcare
    PolicyIbrance (palbociclib) Step Therapy
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionFor applicable new-to-therapy members, document a contraindication, intolerance, or inappropriateness for both Kisqali and Verzenio.
    SourceLink
    POLICY UPDATE CHANGES

    The July 2026 revision removed the criterion requiring Ibrance to be used in combination with an aromatase inhibitor or Faslodex.

    The policy includes new step therapy criteria requiring consideration of Kisqali and Verzenio for applicable new-to-therapy members.

    2Preferred CDK4/6 inhibitor alternatives
    12 monthsAuthorization duration
    <19 yearsAutomatic processing age threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HR+ / HER2−Tumor biomarker profile
    NegativePIK3CA mutation status

    Coverage Criteria

    Patients Less Than 19 Years of Age

    Covered when the following criterion is met:

    Age criterion: Member is less than 19 years of age<19 years

    Authorization will be issued for 12 months.

    HR-Positive, HER2-Negative, PIK3CA Activating Mutation-Negative Recurrent Unresectable or Stage IV Breast Cancer

    Covered when the disease criterion is met and ANY one of the following pathways applies:

    Disease and applicable pathway

    • Disease indication: Member has hormone receptor-positive, HER2-negative, PIK3CA activating mutation-negative recurrent unresectable (local or regional) or stage IV (M1) breast cancerHR-positive / HER2-negative / PIK3CA activating mutation-negative
    • Coverage pathway

      • Alternative-drug exception: Provider attests that the patient has a contraindication, history of intolerance, or is not an appropriate candidate for both Kisqali (ribociclib) and Verzenio (abemaciclib), and documents the reason for each applicable alternative.Both alternatives addressed

        Applies to patients new to therapy.

      • Continuation pathway: Ibrance is being continued and the patient has not received a manufacturer-supplied sample at no cost from a prescriber's office, any form of assistance from the Pfizer Oncology Together patient support program, or a 30-day free trial from a pharmacy as a means to establish current Ibrance use.Continuation of therapy

        Patients established through these free-supply or assistance mechanisms must meet initial authorization criteria as new to therapy.

    A member requesting initial authorization who became established on Ibrance solely through a manufacturer-supplied sample at no cost, assistance from the Pfizer Oncology Together patient support program, or a 30-day free pharmacy trial is not eligible for the continuation pathway. The member must instead satisfy the initial authorization criteria.

    Initial Therapy

    Initial Therapy

    Initial authorization is covered when ALL of the following are met:

    Initial authorization requirements

    • Disease indication: Member has HR-positive, HER2-negative, PIK3CA activating mutation-negative recurrent unresectable or stage IV breast cancerHR-positive / HER2-negative / PIK3CA activating mutation-negative
    • Step-therapy exception: Provider documents that the member has a contraindication, history of intolerance, or is not an appropriate candidate for both Kisqali (ribociclib) and Verzenio (abemaciclib), with the reason documented for each alternative.Both Kisqali and Verzenio addressed

    Continuation Therapy

    Continuation Therapy

    Continuation may qualify for coverage when ALL of the following are met:

    Continuation requirements

    • Ibrance is being continuedContinuation of therapy
    • The patient has not received a manufacturer-supplied sample at no cost from a prescriber's office, any form of assistance from the Pfizer Oncology Together patient support program, or a 30-day free trial from a pharmacy as a means to establish current Ibrance use.

      If the patient was established through one of these mechanisms, initial authorization criteria apply.

    Preferred CDK4/6 Inhibitor Step Therapy

    StepAlternative therapies to addressRequirement before Ibrance coverage
    1Kisqali (ribociclib) and Verzenio (abemaciclib)For applicable new-to-therapy members with HR-positive, HER2-negative, PIK3CA activating mutation-negative recurrent unresectable or stage IV breast cancer, the provider must document a contraindication, history of intolerance, or that the member is not an appropriate candidate for both therapies, including the reason for each.

    Provider Documentation and Action Items

    Documentation Required

    Meet Applicable Coverage Criteria

    Apply the applicable coverage criteria for Ibrance. For members younger than 19 years, the prescription processes automatically without a coverage review; when reviewed, the age criterion is that the member is younger than 19 years, with authorization issued for 12 months. For the specified HR-positive, HER2-negative, PIK3CA activating mutation-negative recurrent unresectable or stage IV breast cancer indication, coverage requires either an approved exception to both preferred therapies or documented continuation of therapy. State mandates, federal requirements, the member-specific benefit plan, and other utilization-management programs may supersede or affect these criteria.

    • Members younger than 19 years: automatic processing without coverage review.
    • Authorization period: 12 months when authorization is issued.
    • Other indications: coverage may be subject to applicable state mandates and benefit-specific requirements.
    Step Therapy

    Satisfy Ibrance Step Therapy

    For a new-to-therapy member requesting Ibrance for HR-positive, HER2-negative, PIK3CA activating mutation-negative recurrent unresectable or stage IV breast cancer, address the required step-therapy pathway before requesting coverage. The request must show that both preferred CDK4/6 inhibitors have been considered, unless the member qualifies for the documented alternative-drug exception.

    Clinical Background

    Ibrance (palbociclib) is a CDK4/6 kinase inhibitor used with endocrine-based therapy for hormone receptor-positive (HR-positive), HER2-negative advanced or metastatic breast cancer. The CDK4/6 inhibitor class also includes Kisqali (ribociclib) and Verzenio (abemaciclib).

    Key Definitions

    HR-Positive, HER2-Negative
    Hormone receptor statusHormone receptor-positive (HR+) breast cancer
    HER2 statusNegative for human epidermal growth factor receptor 2 (HER2-negative)
    Policy contextThe biomarker profile used for the specified Ibrance coverage criterion is HR-positive and HER2-negative.
    CDK4/6 Inhibitor
    ClassCyclin-dependent kinase 4 and 6 (CDK4/6) kinase inhibitor
    IbrancePalbociclib (Ibrance)
    KisqaliRibociclib (Kisqali)
    Policy Summary
    PayerUnitedHealthcare
    PolicyIbrance (palbociclib) Step Therapy
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionFor applicable new-to-therapy members, document a contraindication, intolerance, or inappropriateness for both Kisqali and Verzenio.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation TherapyPreferred CDK4/6 Inhibitor Step TherapyProvider Documentation and Action ItemsClinical BackgroundKey Definitions
    • Required preferred alternatives: Kisqali (ribociclib) and Verzenio (abemaciclib).
    • Continuation-of-therapy requests follow the separate continuation pathway described below.
    Step Therapy

    Address Both Preferred CDK4/6 Inhibitors

    For applicable new-to-therapy members, document consideration of both preferred CDK4/6 inhibitors—Kisqali and Verzenio—as part of the Ibrance coverage request.

    • Kisqali (ribociclib)
    • Verzenio (abemaciclib)
    Documentation Required

    Document Alternative-Drug Exception

    If the member has not used both preferred alternatives, provide a provider attestation that the member has a contraindication, a history of intolerance, or is not an appropriate candidate for both Kisqali and Verzenio. Document the specific reason for each applicable alternative.

    • The exception must address both Kisqali and Verzenio.
    • A general statement is insufficient; document the contraindication, intolerance, or inappropriateness.
    Documentation Required

    Document Continuation Status

    For a continuation request, document that the patient is continuing Ibrance therapy and confirm that continuation is not being established solely through free or manufacturer-supplied access. Patients initially established through such access must be evaluated under the initial-authorization criteria as new to therapy.

    • Continuation requires both documented continuation of therapy and confirmation that the excluded free-supply circumstances did not establish current-user status.
    • Authorization is issued for 12 months when approved.
    Denial Risk

    Failure to Meet Step Therapy Criteria

    If an applicable new-to-therapy member does not meet the Ibrance step-therapy requirements and no qualifying exception is documented, the request does not satisfy the coverage criteria for the specified indication.

    • Document either the required consideration of both preferred alternatives or a qualifying exception for both.
    • Continuation criteria do not replace initial step-therapy requirements when the patient was established through excluded free-access methods.
    Denial Risk

    Free Supply Does Not Establish Continuation Status

    Manufacturer samples and free-access programs do not establish continuation status for Ibrance. Do not use a no-cost prescriber-office sample, Pfizer Oncology Together assistance—including a sample card redeemable at a pharmacy—or a 30-day free pharmacy trial as evidence that the patient is a current user.

    • These access methods cannot establish continuation of therapy.
    • Patients established through these methods must meet initial-authorization criteria as new to therapy.
    VerzenioAbemaciclib (Verzenio)
    Treatment contextUsed in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
    Recurrent Unresectable or Stage IV (M1) Breast Cancer
    RecurrentBreast cancer that has returned after prior treatment.
    UnresectableDisease that cannot be surgically removed in a local or regional location.
    Stage IV (M1)Breast cancer with distant metastasis, classified as stage IV (M1).
    Policy terminologyThe specified coverage criterion refers to recurrent unresectable (local or regional) or stage IV (M1) breast cancer.